Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.

Authors

Joseph B. Babigumira

University of Washington, Seattle, WA

Joseph B. Babigumira , Eduardo Santos , Vincent Percival Antao , Bruce Wang , Chia C. Portera , Tripthi Kamath , Louis P Garrison

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer.

First Author: Nicholas Patrick McAndrew

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.

First Author: Hong-Fei Gao

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).

First Author: Laura Spring

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Pathologic complete response rates observed in women with locally advanced and inflammatory breast cancer receiving neoadjuvant carboplatin and paclitaxel.

First Author: Arvind Manohar Shinde